

# ICC Intl Cannabis Corp.

08:22 22 Feb 2019

## ICC International Cannabis on a quest to capture market share

ICC International Cannabis Corp (CSE:WRLD.U) (OTCMKTS:WLDCF) has stepped up efforts to gain market share in the cannabis space.

In an update to investors Friday, the company talked up its medical cannabis and cannabidiol (CBD) portfolio.

Over the past three quarters, the Vancouver company has embarked on an aggressive acquisition strategy, which includes an agreement to acquire 49.9% of Wayland Group Corp's international assets and license portfolio.

### READ: ICC International Cannabis announces two strategic hemp deals, which will allow it to start fulfilling orders

"International Cannabis is uniquely positioned to capture significant market share as the European THC and CBD industries continue to mature," said Eugene Beukman, CEO and a director of International Cannabis. "We have tactically secured cornerstone assets in Denmark and Germany - jurisdictions armed with broad insurance coverage, affording the company the ability to realize substantially higher margins, while insulating our operations from margin compression."

Upon the closing of the Wayland deal, ICC will boast an array of new operations, partnerships, licenses and assets.

On the list of what it will acquire are a German medical cannabis import license as well as a Danish medical THC cultivation and manufacturing facility. It will also gain an 820,000 square foot production facility in Ebersbach, which is just outside of Dresden, Germany.

The Wayland partnership will help to widen ICC's business across continental Europe as it will also provide a Polish hemp processing and extraction license; a Portuguese hemp cultivation and processing license; a Maltese license to manufacture medical cannabis; a license in Bulgaria for the production, manufacturing and export of hemp and medical cannabis; and a 60,000 square foot Swiss cannabis cultivation facility.

The company is moving into Africa too, with the gaining of licenses for medical cannabis cultivation, manufacturing, distribution and import/export in the Kingdom of Lesotho. It is also picking up supply agreements to provide cannabis products to over 2,800 independent and corporate pharmacies across South Africa.

Colombia is in its sights as well, as ICC is securing licenses for THC/CBD production, extraction and export in the country.

Lastly, the company is looking to acquire medical cannabis licenses in the UK, Australia and Argentina.

ICC International Cannabis shares closed up 2.8% to hit C\$0.36 on Thursday.

Contact Ellen Kelleher at [ellen@proactiveinvestors.com](mailto:ellen@proactiveinvestors.com)

### 1 Year Share Price Graph



### Share Information

**Code:** WRLD.U  
**Listing:** CSE  
**Sector:** Cannabis  
**Website:** [intlcannabiscorp.com](http://intlcannabiscorp.com)

### Company Synopsis:

*ICC International Cannabis' corporate mandate is to plan, design, build and operate the highest quality, lowest cost Cannabis production, processing and distribution facilities worldwide. ICC boasts an in-depth understanding of both the cannabis and biomedical industries, as well as world-class experience within the many associated cannabis industry vehicles and derivatives.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of ICC Intl Cannabis Corp. named herein, including the promotion by the Company of ICC Intl Cannabis Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).